Vinblastine News and Research

RSS
Vinblastine is the active ingredient in a drug used together with other drugs to treat several types of cancer, including advanced Hodgkin lymphoma and advanced testicular germinal-cell cancers. It is also being studied in the treatment of other types of cancer. Vinblastine comes from the periwinkle plant Vinca rosea Linn. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of vinca alkaloid and a type of antimitotic agent.
Innovative technique speeds up search for antimicrobial drug candidates

Innovative technique speeds up search for antimicrobial drug candidates

NCCN survey reveals ongoing shortages in crucial cancer medications

NCCN survey reveals ongoing shortages in crucial cancer medications

Advances in Diels-Alder synthesis of hydrocarbazole compounds using lanthanide catalysts

Advances in Diels-Alder synthesis of hydrocarbazole compounds using lanthanide catalysts

Genetically engineered yeast cells produce natural plant product for schizophrenia treatment

Genetically engineered yeast cells produce natural plant product for schizophrenia treatment

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

Did the diagnosis and management of Hodgkin lymphoma differ during the SARS-CoV-2 pandemic?

Did the diagnosis and management of Hodgkin lymphoma differ during the SARS-CoV-2 pandemic?

Biomarker could predict pathologic response to chemotherapy among bladder cancer patients

Biomarker could predict pathologic response to chemotherapy among bladder cancer patients

Polymeric nanomicelles effectively deliver anti-cancer drugs to glioblastoma

Polymeric nanomicelles effectively deliver anti-cancer drugs to glioblastoma

Study shows superior functionality of Duodenum Intestine-Chip populated with organoids

Study shows superior functionality of Duodenum Intestine-Chip populated with organoids

Increasing anti-tumor activity of compound extracted from an Amazon plant

Increasing anti-tumor activity of compound extracted from an Amazon plant

Patients with advanced Hodgkin's lymphoma may benefit from radiotherapy after chemotherapy

Patients with advanced Hodgkin's lymphoma may benefit from radiotherapy after chemotherapy

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Finding which chemotherapy regimen is associated with best outcomes for patients with bladder cancer

Finding which chemotherapy regimen is associated with best outcomes for patients with bladder cancer

OSU scientists find way to fight solid tumors using new cancer-drug delivery system

OSU scientists find way to fight solid tumors using new cancer-drug delivery system

Chemotherapy drug combination appears to increase production of eggs in women's ovaries

Chemotherapy drug combination appears to increase production of eggs in women's ovaries

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

UQDI reveals that Anisina drug can kill melanoma cells

UQDI reveals that Anisina drug can kill melanoma cells

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.